Published in Pain and Central Nervous System Week, April 25th, 2005
Researchers examined data from a previous trial involving 917 smokers randomized to a placebo or to the 2 mg Commit lozenge marketed by GlaxoSmithKline (GSK) Consumer Healthcare. They found that 2 mg Commit can significantly increase light smokers' chances of quitting successfully. The analysis is the first of its kind that focuses specifically on light smokers, defined as people who smoke 15 cigarettes per day or less, and who smoke their first cigarette of the day more than 30 minutes after waking, an indicator of low tobacco dependence.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.